Josh Bilenker ends his brief role in an unusual experiment at Eli Lilly, bowing out as head of their Loxo cancer R&D unit

A little more than a year since Josh Bilenker started an unusual experiment running Eli Lilly’s cancer research group following the $8 billion …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Josh Bilenker ends his brief role in an un­usu­al ex­per­i­ment at Eli Lil­ly, bow­ing out as head of their Loxo can­cer R&D unit